|
| Issue Date | Title | Author(s) |
| 2010 | Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations | Yeo, W.-L. ; Lau, M.W.; Warner, J.L.; Bodio, K.; Huberman, M.S.; Tenen, D.G. ; Kobayashi, S.; Costa, D.B.; Riely, G.J.; Kris, M.G.; Yeap, B.Y.; Pao, W. |
| Jun-2011 | Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials | Soo, R.A. ; Loh, M. ; Mok, T.S.; Ou, S.-H.I.; Cho, B.-C.; Yeo, W.-L. ; Tenen, D.G.; Soong, R. |
| Sep-2011 | Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients | Wong, A.L.-A.; Yap, H.-L.; Yeo, W.-L. ; Soong, R.; Ng, S.-S.; Wang, L.-Z.; Cordero, M.T.; Yong, W.-P. ; Goh, B.-C.; Lee, S.-C. |
| Nov-2011 | Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer | Wong, N.-S.; Seah, E.Z.H.; Wang, L.-Z.; Yeo, W.-L. ; Yap, H.-L.; Chuah, B.; Lim, Y.-W.; Ang, P.C.S.; Tai, B.-C. ; Lim, R.; Goh, B.-C.; Lee, S.-C. |
| 2009 | Lack of somatic mutations in VEGFR-2 tyrosine kinase domain in hepatocellular carcinoma | Chuah, B.Y.S.; Yeo, W.-L. ; Guo, J.Y. ; Lim, S.-G.; Yap, H.-L. ; Goh, B.-C.; Lee, S.-C. |
| Nov-2011 | Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies | Yong, W.P. ; Goh, B.C.; Soo, R.A. ; Toh, H.C.; Ethirajulu, K.; Wood, J.; Novotny-Diermayr, V.; Lee, S.C. ; Yeo, W.L. ; Chan, D.; Lim, D.; Seah, E.; Lim, R.; Zhu, J. |
| Dec-2010 | Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes | Chan, D.; Yeo, W.-L. ; Tiemsim Cordero, M.; Wong, C.-I.; Chuah, B.; Soo, R. ; Tan, S.-H.; Lim, S.-E.; Goh, B.-C.; Lee, S.-C. |
| Aug-2010 | Serum concentrations of erlotinib at a dose of 25 mg daily | Costa, D.B.; Kobayashi, S.; Yeo, W.-L. ; Hamada, A. |
